1900 Wealth Management LLC Has $416,000 Stock Holdings in Eli Lilly and Company (NYSE:LLY)

1900 Wealth Management LLC reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 30.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 538 shares of the company’s stock after selling 235 shares during the period. 1900 Wealth Management LLC’s holdings in Eli Lilly and Company were worth $416,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. AMF Tjanstepension AB grew its stake in shares of Eli Lilly and Company by 113.7% in the third quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock worth $293,964,000 after acquiring an additional 176,552 shares during the last quarter. Brendel Financial Advisors LLC boosted its stake in Eli Lilly and Company by 5.9% in the 3rd quarter. Brendel Financial Advisors LLC now owns 2,192 shares of the company’s stock valued at $1,942,000 after buying an additional 122 shares in the last quarter. B & T Capital Management DBA Alpha Capital Management lifted its holdings in Eli Lilly and Company by 748.9% during the 3rd quarter. B & T Capital Management DBA Alpha Capital Management now owns 3,073 shares of the company’s stock valued at $2,722,000 after purchasing an additional 2,711 shares during the last quarter. Strategic Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 1.7% in the 3rd quarter. Strategic Advisors LLC now owns 1,633 shares of the company’s stock worth $1,447,000 after acquiring an additional 28 shares in the last quarter. Finally, Boston Common Asset Management LLC grew its holdings in Eli Lilly and Company by 77.5% during the 3rd quarter. Boston Common Asset Management LLC now owns 18,563 shares of the company’s stock worth $16,446,000 after acquiring an additional 8,106 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Bank of America reiterated a “buy” rating and set a $997.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Deutsche Bank Aktiengesellschaft decreased their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Barclays lowered their target price on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. Finally, Sanford C. Bernstein initiated coverage on shares of Eli Lilly and Company in a research report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price target on the stock. Four research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $997.50.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $878.09 on Friday. The stock has a market capitalization of $833.59 billion, a price-to-earnings ratio of 94.93, a PEG ratio of 1.72 and a beta of 0.42. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The firm has a fifty day simple moving average of $788.21 and a 200 day simple moving average of $843.47. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. Research analysts forecast that Eli Lilly and Company will post 12.85 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.68%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

Eli Lilly and Company declared that its board has authorized a stock repurchase plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its shares are undervalued.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.